Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...
Leerink Partners analyst Daina Graybosch cautioned against too much pessimism, writing “this continued uncertainty is likely ...
Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...
Barchart on MSN11d
What Are Wall Street Analysts’ Target Price for Merck Stock?Rahway, New Jersey-based Merck & Co., Inc. (MRK) functions as a healthcare company. Valued at $252.4 billion by market cap, ...
Across the recent three months, 12 analysts have shared their insights on Merck & Co (NYSE:MRK), expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback